의약품 CRO 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 분자 유형별, 서비스별, 치료 분야별, 지역별, 부문별 예측(2024-2030년)

Pharmaceutical CRO Market Growth & Trends:

The global pharmaceutical CRO market size is expected to reach USD 62.99 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to show a lucrative CAGR of 7.32% over the forecast period due to rising outsourcing trends and increasing R&D expenditure.

Pharmaceutical CROs provide outsourcing services to various pharmaceutical companies on a contract basis. Increasing outsourcing among pharmaceutical companies, growing investments in the R&D of new drugs, expansions in the pharmaceutical industry, and CRO support in reducing operational and capital expenses are some of the major factors anticipated to propel market growth in the forecast period.

Besides, increasing demand for CRO is driven by rising requirements for improved drug development, product maintenance, and related services, which is expected to drive market growth in the coming years. In addition, the substantial presence of key market players and ongoing clinical trials globally are expected to drive market growth. For instance, according to the U.S. National Library of Medicine, about 83,230 clinical trial studies are currently active and recruiting globally, which is anticipated to contribute to market growth. Likewise, increasing drug development activities, strategic initiatives such as innovation & acquisitions, the growing presence of pharmaceutical companies, and a surge in demand for pharmaceutical CRO innovative services are key factors propelling the market growth.

Furthermore, growing technological innovations pertaining to developing novel pharmaceutical drugs and rising research and development for biologics are anticipated to influence the market positively. Currently, pharmaceutical companies are increasingly bolstering their capacities in CRO's newer, highly specific expertise and technologies for the innovation of various small & large molecules. In addition, most pharmaceutical CROs have an emerging demand for small molecule drug candidates' development as CRO supports early discovery and preclinical drug development studies. For instance, in March 2023, Crown Bioscience & JSR Life Sciences Company mentioned it's a new site in Singapore, which will support the company in expanding its capacity for biotech & pharma companies. The site will help companies that engage in preclinical & translational oncology drug discovery and development.

Pharmaceutical CRO Market Report Highlights:

• The clinical segment dominated the market with a revenue share of 75.85% in 2023 due to changing drug development scenarios and the need for sophisticated capabilities to help pharmaceutical companies advance drug manufacturing. In addition, cost-effectiveness and the increasing number of CROs are some of the key factors positively affecting market growth.
• The small molecules segment dominated the market in 2023 owing to the increasing potential of targeted therapies, rising demand for personalized medicine, and pharmaceutical companies' growing interest in small molecules. Besides, the expanding pipeline of small molecule drugs is anticipated to create opportunities for CROs to provide services.
• Based on service, clinical monitoring held the largest market share of 20.15% in 2023, which is attributed to the increase in the adoption of monitoring of regulatory requirements and clinical trial management, which includes protocol development to data analysis, making it a suitable option for a wide range of clinical trials.
• In terms of therapeutic areas, the oncology segment held the largest market share of 30.46% in 2023. The segment is driven by the growing incidence of cancer, the rising aging population, and the robust demand for pharmaceuticals, contributing to its prominence in this field.
• Asia Pacific dominated the market globally with a revenue share of 45.60% in 2023. The region's high share is due to an increased number of actively functioning CROs, especially in China and Japan, among others.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Type Segment
  • 1.2.2. Molecule Type Segment
  • 1.2.3. Services Segment
  • 1.2.4. Therapeutic Areas Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Pharmaceutical CRO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing Rate of Clinical Research to Boost Demand For Outsourcing Services
    • 3.2.1.2. Increasing Adoption of Advanced Technologies
    • 3.2.1.3. Increasing Mergers and Collaborations
    • 3.2.1.4. Increasing Demand for Outsourcing Services Across The Developing Economies
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Risk Associated with Data Security
    • 3.2.2.2. Monitoring Issues and Lack of Standardization
• 3.3. Pharmaceutical CRO Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Pharmaceutical CRO Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Pharmaceutical CRO Market Type Movement Analysis
• 4.3. Global Pharmaceutical CRO Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. Drug Discovery
  • 4.4.1. Drug discovery market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Target Validation
    • 4.4.2.1. Target validation market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Lead Identification
    • 4.4.3.1. Lead identification market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Lead Optimization
    • 4.4.4.1. Lead optimization market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Pre-Clinical
  • 4.5.1. Pre-Clinical market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Clinical
  • 4.6.1. Clinical market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.2. Phase I Trial Services
    • 4.6.2.1. Phase I Trial Services market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.3. Phase II Trial Services
    • 4.6.3.1. Phase II Trial Services market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.4. Phase III Trial Services
    • 4.6.4.1. Phase III Trial Services market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.5. Phase IV Trial Services
    • 4.6.5.1. Phase IV Trial Services market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Pharmaceutical CRO Market: Molecule Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Pharmaceutical CRO Market Molecule Type Movement Analysis
• 5.3. Global Pharmaceutical CRO Market Size & Trend Analysis, by Molecule Type, 2018 to 2030 (USD Million)
• 5.4. Small Molecules
  • 5.4.1. Small Molecules market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Large Molecules
  • 5.5.1. Large Molecules market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Pharmaceutical CRO Market: Services Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Pharmaceutical CRO Market Services Movement Analysis
• 6.3. Global Pharmaceutical CRO Market Size & Trend Analysis, by Services, 2018 to 2030 (USD Million)
• 6.4. Project Management/Clinical Supply Management
  • 6.4.1. Project Management/Clinical Supply Management market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Data Management
  • 6.5.1. Data Management market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Regulatory/Medical Affairs
  • 6.6.1. Regulatory/Medical Affairs market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Medical Writing
  • 6.7.1. Medical Writing market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Clinical Monitoring
  • 6.8.1. Clinical Monitoring market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. Quality Management/ Assurance
  • 6.9.1. Quality Management/ Assurance market estimates and forecasts 2018 to 2030 (USD Million)
• 6.10. Biostatistics
  • 6.10.1. Bio-statistics market estimates and forecasts 2018 to 2030 (USD Million)
• 6.11. Investigator Payments
  • 6.11.1. Investigator Payments market estimates and forecasts 2018 to 2030 (USD Million)
• 6.12. Laboratory
  • 6.12.1. Laboratory market estimates and forecasts 2018 to 2030 (USD Million)
• 6.13. Patient And Site Recruitment
  • 6.13.1. Patient And Site Recruitment market estimates and forecasts 2018 to 2030 (USD Million)
• 6.14. Technology
  • 6.14.1. Technology market estimates and forecasts 2018 to 2030 (USD Million)
• 6.15. Others
  • 6.15.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Pharmaceutical CRO Market: Therapeutic Areas Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Pharmaceutical CRO Market Therapeutic Areas Movement Analysis
• 7.3. Global Pharmaceutical CRO Market Size & Trend Analysis, by Therapeutic Areas, 2018 to 2030 (USD Million)
• 7.4. Oncology
  • 7.4.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. CNS Disorders
  • 7.5.1. CNS Disorders market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Infectious Diseases
  • 7.6.1. Infectious Diseases market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Immunological Disorders
  • 7.7.1. Immunological Disorders market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Cardiovascular Disease
  • 7.8.1. Cardiovascular Disease market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. Respiratory Diseases
  • 7.9.1. Respiratory Diseases market estimates and forecasts 2018 to 2030 (USD Million)
• 7.10. Diabetes
  • 7.10.1. Diabetes market estimates and forecasts 2018 to 2030 (USD Million)
• 7.11. Ophthalmology
  • 7.11.1. Ophthalmology market estimates and forecasts 2018 to 2030 (USD Million)
• 7.12. Pain Management
  • 7.12.1. Pain Management market estimates and forecasts 2018 to 2030 (USD Million)
• 7.13. Other
  • 7.13.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Pharmaceutical CRO Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2023 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.4. North America
  • 8.4.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Competitive scenario
    • 8.4.2.3. Regulatory Landscape
    • 8.4.2.4. Reimbursement Scenario
    • 8.4.2.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Competitive scenario
    • 8.4.3.3. Regulatory Landscape
    • 8.4.3.4. Reimbursement Scenario
    • 8.4.3.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Competitive scenario
    • 8.4.4.3. Regulatory Landscape
    • 8.4.4.4. Reimbursement Scenario
    • 8.4.4.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Competitive scenario
    • 8.5.2.3. Regulatory Landscape
    • 8.5.2.4. Reimbursement Scenario
    • 8.5.2.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Competitive scenario
    • 8.5.3.3. Regulatory Landscape
    • 8.5.3.4. Reimbursement Scenario
    • 8.5.3.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Competitive scenario
    • 8.5.4.3. Regulatory Landscape
    • 8.5.4.4. Reimbursement Scenario
    • 8.5.4.5. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Competitive scenario
    • 8.5.5.3. Regulatory Landscape
    • 8.5.5.4. Reimbursement Scenario
    • 8.5.5.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Competitive scenario
    • 8.5.6.3. Regulatory Landscape
    • 8.5.6.4. Reimbursement Scenario
    • 8.5.6.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Competitive scenario
    • 8.5.7.3. Regulatory Landscape
    • 8.5.7.4. Reimbursement Scenario
    • 8.5.7.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.8. Norway
    • 8.5.8.1. Key country dynamics
    • 8.5.8.2. Competitive scenario
    • 8.5.8.3. Regulatory Landscape
    • 8.5.8.4. Reimbursement Scenario
    • 8.5.8.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.9. Sweden
    • 8.5.9.1. Key country dynamics
    • 8.5.9.2. Competitive scenario
    • 8.5.9.3. Regulatory Landscape
    • 8.5.9.4. Reimbursement Scenario
    • 8.5.9.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Competitive scenario
    • 8.6.2.3. Regulatory Landscape
    • 8.6.2.4. Reimbursement Scenario
    • 8.6.2.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Competitive scenario
    • 8.6.3.3. Regulatory Landscape
    • 8.6.3.4. Reimbursement Scenario
    • 8.6.3.5. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Competitive scenario
    • 8.6.4.3. Regulatory Landscape
    • 8.6.4.4. Reimbursement Scenario
    • 8.6.4.5. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Competitive scenario
    • 8.6.5.3. Regulatory Landscape
    • 8.6.5.4. Reimbursement Scenario
    • 8.6.5.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Competitive scenario
    • 8.6.6.3. Regulatory Landscape
    • 8.6.6.4. Reimbursement Scenario
    • 8.6.6.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Competitive scenario
    • 8.6.7.3. Regulatory Landscape
    • 8.6.7.4. Reimbursement Scenario
    • 8.6.7.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Competitive scenario
    • 8.7.2.3. Regulatory Landscape
    • 8.7.2.4. Reimbursement Scenario
    • 8.7.2.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Competitive scenario
    • 8.7.3.3. Regulatory Landscape
    • 8.7.3.4. Reimbursement Scenario
    • 8.7.3.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Competitive scenario
    • 8.8.2.3. Regulatory Landscape
    • 8.8.2.4. Reimbursement Scenario
    • 8.8.2.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Competitive scenario
    • 8.8.3.3. Regulatory Landscape
    • 8.8.3.4. Reimbursement Scenario
    • 8.8.3.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key country dynamics
    • 8.8.4.2. Competitive scenario
    • 8.8.4.3. Regulatory Landscape
    • 8.8.4.4. Reimbursement Scenario
    • 8.8.4.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key country dynamics
    • 8.8.5.2. Competitive scenario
    • 8.8.5.3. Regulatory Landscape
    • 8.8.5.4. Reimbursement Scenario
    • 8.8.5.5. Israel market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2023
• 9.4. Company Profiles/Listing
  • 9.4.1. Parexel International (MA) Corporation.
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. ICON plc
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Laboratory Corporation of America Holdings
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Thermo Fisher Scientific Inc.
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Medpace
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. IQVIA
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. CTI Clinical Trial & Consulting
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. WuXi AppTec
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Veeda Clinical Research
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives